Summary lular restoration of both metabolic and bactericidal capacities of
IgG-coated liposomes containing glucose oxidase (GO) in order to provide a means of generating Hz02 were prepared. Leukocytes from patients with chronic granulomatous disease (CGD) which are lacking a means of generating HzO2, ingested the IgG-coated liposomes and metabolic oxidative deficiencies of glucose-1-"C oxidation and iodination were normalized. Both of these activities have been shown to depend upon the availability of Hz02 within polymorphonuclear leukocytes. Improvement in the capacity to kill Staphylococcus aureus by chronic granulomatous disease leukocytes were observed under similar conditions. Thus, it is possible to restore the oxidative metabolic capacities to CGD leukocytes by the introduction of glucose oxidase containing liposomes to these cells.
Speculation
It is possible to restore the oxidative metabolic capacities and to obtain moderate improvement in the bactericidal functions in vitro of CGD leukocytes by providing the cells ingestible liposomes containing GO. Further studies might define more efficient methods for introducing oxidase activity into these cells, or employing drugs that generate H20z.
CGD is a genetic disorder of leukocyte function characterized by lack of normal oxidative metabolic activities associated with phagocytosis. These oxidative activities include, in part, increased glucose-I-"C metabolism (13) , iodination of ingested particles (21) , and production of superoxide anion (0;) (9), and hydrogen peroxide (HzOz) (1, 14) which are necessary for efficient killing of catalase positive microorganism (18, 20) . I n vitro improvement of the metabolic and bactericidal deficiencies of CGD leukocytes has been achieved utilizing glucose-oxidase coated latex particles (5, 17) and an HzOTproducing dapsone derivative, 4-hydroxylaminodiphenyl sulfone (16) . The enhanced metabolic response of the CGD leukocyte could be ascribed to both extracellular and intracellular elaboration of HzOz. Recently, enzyme replacement therapy utilizing liposomes as camers of entrapped enzyme has been employed as a means to specifically replace the deficient enzyme (10, 28) . Liposome utilization eliminates the risk of directly introducing immunogenic foreign proteins into the circulation and delivers entrapped enzyme to selective target cells. Despite intensive attempts to identify the enzymatic basis for lack of enhanced enzyme activity during phagocytosis by CGD leukocytes, the failure of these cells to reduce oxygen indicates either a missing or defective oxidase (2, 4, 7, 12) . However, it is generally agreed that the pathologic basis for recurrent infection lies with the failure of these PMNs 'o generate HzOz and other oxidants (4, 9, 14) . In this study, substitution of an HZ0z-generating enzyme, glucose oxidase in liposomes opsonized with IgG, allowed for selective intracel-CGD leukocytes utilizing GO containing liposomes
MATERIALS AND METHODS

SOURCES AND PREPARATION OF PMN LEUKOCYTES
Venous blood was collected from normal adult volunteers and three unrelated patients with CGD. The diagnosis was confirmed in each case by the failure of the leukocytes to reduce nitroblue tetrazolium dye (4) and to kill S. aureus 502A normally (24) . The leukocytes were separated from the heparinized blood by sedimentation of the erythrocytes at 37OC with 6% dextran (Pharmacia Fine Chemicals, Ind., Piscataway, NJ). The leukocyte-rich fraction was centrifuged at 250 g for 10 min at 4°C and contaminating erythrocytes were removed by hypotonic lysis. IgG-Lip-GO were prepared as previously described by Weissman et al. (27) . L-a-Lecithin (L-a-phosphatidyl choline) from egg yolk, dicetyl phosphate, and cholesterol were purchased from Sigma. Chemical Co., St. Louis, Missouri. Briefly, lecithin, dicetyl phosphate, and cholesterol were dissolved in chloroform and added to a 100 ml round bottom flask at a molar ratio of 7:2:1 in a total volume of 6 ml. The lipids were dried using a rotary flashevaporator (Buchler Instrument, Fort Lee, NJ) in a 37°C water bath until a uniform thin lipid layer was formed on the walls. A 4 ml aqueous solution of either active GO or heat-inactivated GO (100°C for 30 min) at a concentration of 1.0 unit/ml was added and the flask was flooded with NZ gas. Two glass beads were added to the flask and the lipid film was dislodged off the wall by vortexing. The preparation was briefly sonicated at 4°C with a Bronson sonifier, Model W140, at a setting of 3 for four intermittent 15-sec periods. The resulting cloudy suspension was allowed to swell at room temperature for 2 hr and layered on a Sepharose 4B column (2.7 X 36 cm) equilibrated with 6.7 mM phosphate buffer, pH 7.2. Liposomes were eluted and the effluents were collected in 5 rnl fractions. The fractions were analyzed for lipid content by determining absorbance at 520 nm. Glucose oxidase activity was determined as described previously (8) . Latent glucose oxidase activity in the liposomes was determined after incubation of the fractions with an equal volume of 1% Triton X-100 at 37OC for 30 min. The liposome-rich fractions were pooled and centrifuged at 100,000 g for 1 hr. The pellet was suspended in 0.1M phosphate buffered saline and adjusted to an optical density of 0.4 at 530 nm.
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ISMAIL, BOXER. AND BAEHNER
Human IgG was obtained from Miles Laboratory, Inc., Elkhart,
MEASUREMENT OF GLUCOSE-I-"C OXIDATION
Indiana. a& used without further purification. i h e lyophilized ~h , hexose m o n o p~o s p~a~e shunt (HMP) activity was deter-I~G was reconstituted with 0.01M phosphate buffer (pH 6-51 and mined as previously described by Baehner et al. (1) . The incubathe pH was adjusted to 7.3 with 1M Na2HPO4. The IgG solution tion mixture contained 0.5 ml o f p~~ (1 107 cells/ml), 1 p~i of was heat-aggregated for 10 min at 6z0C, then incubated with glucose-l-i4~, 0.1 ml fresh human serum and various concentraliposomes for 25 min at 37°C (100 pg Agg-IgG/ml).
tions of IgG-Lip-GO. As appropriate, the reaction mixture was (1 x lo7 cells/ml), 0.5 ml of IgG-Lip-GO and 0.2 ml of fresh normal serum. The tubes were incubated for 60 min in a 37°C
MEASUREMENT OF IODINATION ACTIVITY
shaking water bath. To determine the ability of PMN to ingest IgG-Lip-GO, phagocytosis was blocked either by the addition of cytochalasin B (5 M m l ) or by placing the tubes in ice bath. After incubation, the tubes were centrifuged at 250 g for 10 min and the pellets were washed three times before resuspending in 0.5 ml of phosphate buffered saline, pH 7.
3. An equal volume of 1% Triton X-100 was added and the solutions were sonicated for three 15-sec periods at 4OC to ensure complete release of glucose oxidase from both the cells and the liposomes.
MEASUREMENT OF Hz02 RELEASE FROM PMN LEUKOCYTES
PMN were incubated with IgG-Lip-GO as described above. Sodium azide (1 mM) was added to the leukocyte previously to inhibit catalase and prevent the breakdown of Hz02 released from the cells. After 30 min of incubation, the tubes were centrifuged at 30,000 rpm for 25 min and the supernatants were placed on ice for later quantitation of Hz02 release. The rate of Hz02 release into the extracellular medium by CGD leukocytes during phagocytosis of IgG-Lip-GO was measured by a modification of the method described by Root et a1. (26) . Briefly, 0.4 ml of 50 pM scopoletin (Sigma Chemical Co.) was added to the supernatant and the tubes were incubated for an additional 30 min. Next, 0.4 ml of horseradish peroxidase (1 mg/ml) was added and the decrease in fluorescence was monitored in a spectrophotofluorimeter using KRP as the blank. The amount of H202 released was calculated from a standard H202 curve using an extinction coefficient of 81M-' at 230 nm (15) .
The iodination of opsonized zymosan particles ingested by PMN leukocytes was determined as previously described by Hakim et al. (1 1). The reaction mixture contained 0.5 ml PMN (1 x lo7 cells/ml), 4 nm ( I '~~) -N~I , 0.1 ml zymosan (ml/ml), and various concentrations of IgG-Lip-GO. The reaction volume was adjusted to 1.0 ml with KRP. Normal PMN phagocytuig opsonized zymosan served as the positive control for increased iodination activity.
MEASUREMENT OF BACTERICIDAL ACTIVITY
The bacterial killing assay was performed by a modification of the method described by Quie et al. (24) . The reaction mixture contained 0.5 ml of PMN leukocytes (5 X lo6 cells/ml), 0.1 ml fresh human serum, and 0.4 ml S. aureus 502A (approximately 5 x 10' bacteria/ml), and 0.1 or 0.2 ml of IgG-Lip-GO.
RESULTS
ENTRAPPING AND LATENCY OF GLUCOSE OXIDASE WITHIN LIPOSOMES
A representative elution profile of the liposome preparation obtained from Sepharose 4B column is shown in Figure 1 
LIPOSOME USE FOR CORRECTION OF DEFICIENCIES
771 activity in the fractions, corresponding to the lipid peak. Glucose oxidase activity associated with the lipid fractions varied from one preparation to another, but as much as 5-1 1% of the total glucose oxidase activity was latent within these lipid fractions.
PHAGOCYTOSIS OF IgG-LipGO
After phagocytosis of IgG-Lip-GO, glucose oxidase activity was demonstrated in the cellular pellet ( Table 1 ). The pellet contained 2-fold greater enzyme activity ( P < 0.025) than those pellets obtained from cells in which phagocytosis was inhibited by either cytochalasin B or ice bath temperatures. Correspondingly, glucose oxidase activity in the supernatant was inversely related to the amount of enzyme activity in the respective pellets. These observations suggest that the liposomes were internalized by the CGD leukocytes. Hz01 
RELEASE
To determine whether the IgG-Lip-GO released enzymatically active glucose oxidase after ingestion, the rate of Hz02 release into the extracellular medium during phagocytosis was quantitated. As noted in Table 2 , Hz02 production by CGD leukocytes was negligible during resting states and failed to increase significantly ( P < 0.4) during ingestion of latex particles. The addition of IgGLip-GO increased the rate of H202 release by approximately 25-fold. Treatment of the CGD PMN with cytochalasin B signscantly ( P < 0.001) attenuated the amount of Hz02 release after .exposure of these cells to IgG-Lip-GO. In a separate experiment, cytochalasin B failed to lyse the IgG-Lip-GO (data not shown). It would, therefore, appear that cytochalasin B treatment only partially inhibits the uptake of the IgG-Lip-GO permitting some generation of H202 by the CGD leukocytes to occur.
GLUCOSE-1-"C OXIDATION
In contrast to normal PMN, incubation of CGD leukocytes with latex particles did not stimulate HMP shunt activity (Table  3 ). In the presence of IgG-Lip-GO, HMP shunt activity was significantly increased ( P < 0.025) in the PMN leukocytes of all CGD patients studied. The stimulation was proportional to the amount of liposomes present in the incubation mixture. An increase of glucose-1-14C oxidation up to 5-fold was observed in samples treated with 0.3 ml of IgG-Lip-GO and the enhanced activity was prevented by heat inactivation of glucose oxidase. Liposomes containing either active or heat-inactivated GO also served as a phagocytic particle for normal PMN, but were less efficient than latex particles in stimulating glucose~l-"C oxidation.
IODINATION ACTIVITY BY PMN LEUKOCYTES
Phagocytosis of opsonized zymosan particles did not increase the iodination activity by CGD leukocytes (Table 4 ). However, iodiiation activity was significantly increased ( P < 0.025) by leukocytes during phagocytosis of IgG-Lip-GO obtained from three patients with CGD. There was increasing iodinating activity with further addition of liposomes. Liposomes containing heatinactivated GO did not increase the iodination activity by CGD leukocytes. T h e simultaneous addition of liposomes containing either active GO or heat-inactivated GO and opsonized zymosan Table 1 . Distribution of GO activity detected after decreased the iodjnation activity of normal PMN compared to the activity obtained with zymosan alone.
BACTERICIDAL ACTIVITY OF NORMAL AND CGD LEUKOCYTES
The capacity of CGD leukocytes to k i d S. aureus 502A was markedly impaired when compared to the killing response obtained with normal PMN (Fig. 2) . In the presence of IgG-Lip-GO, ' Mean of I experiment, each done in duplicate.
'AGO = heat-inactivated GO.
improvement in the killing capacity of CGD leukocytes was consistently obtained. Although the extent of killing by CGD PMN in the presence of IgG-Lip-GO never reached the bactericidal eff~ciency of normal leukocytes, the partial correction was observed both early and at later phases of the 100-min incubation period.
DISCUSSION
The current therapeutic approach for treatment of infections in patients with CGD involves the administration of antibiotics specifically designed to erradicate the causative microorganisms. Because the infecting-catalase positive bacteria destroy their endogenous hydrogen peroxide and the CGD leukocyte is unable to generate hydrogen peroxide during phagocytosis, therapies have been designed to deliver hydrogen peroxide to the deficient CGD cells. Previous attempts to correct the intracellular defect in CGD using drugs have employed methylene blue (23), sulfisoxazole (19), trimethoprim sulfamethoxazole (22) , and a dapsone derivative, 4-hydroxylaminodiphenyl sulfone (16) , but this appraoch has only been partially successful.
Enzyme replacement is another potential method for correction of the oxidative deficiency in these cells. Previously, glucose oxidase bound to latex particles was introduced into CGD leukocytes in vitro as a means of providing hydrogen peroxide (5) . Although improvement of the metabolic and bactericidal defect of the CGD leukocyte was obtained, the source of the hydrogen peroxide was both extracellular and intracellular. Coated latex particles could not be utilized in vivo because of the risk of inciting hypoglycemia, immune complex formation, and pulmonary embarrassment. These problems could be potentially circumvented by utilization of I~G-coated liposomes which could shield the glucose oxidase, until its selective uptake by host phagocytic cells. To test whether IgG-Lip-GO could be employed in vivo, it was necessary to evaluate their function in vitro. Of the total glucose oxidase added to liposomal preparations 5-11% could be entrapped and was only available for utilization after digestion by detergent or by phagocytic cells. surface by both electrostatic and hydrophobic interactions. The Fc portion of the IgG molecule was exposed (27) . and rendered the liposomes phagocytic. The studies were conducted in the absence of fresh serum since complement has been shown to lysis liposomes (25) . The CGD leukocytes ingested the IgG-Lip-GO after phagocytosis and metabolic oxidative deficiencies of glucose-l-"C oxidation and iodination were normalized. Both of these activities have been shown to depend upon the availability of Hz02 within the PMN (3, 18) . On the other hand, the administration of enzyme laden liposomes to normal leukocytes failed to enhance their already stimulated phagocytes of oxidative metabolism. As others , have observed, we found that cytochalasin B incompletely affected the uptake of particles (29) . A modest, but reproducible improvement in the capacity to kill S. aureus by CGD leukocytes was observed under similar conditions. The mechanism for the improved killing capacity can be attributed to the presence of a potent H201 generating system within the phagocytic vacuole which has been previously shown to prove the substrates to complete the peroxidative iodination and killing response for viable pathogenic bacteria (20) . Our inability to completely correct kiiliig by CGD leukocytes may be related to several intracellular and extracellular effects, including steric hinderance to normal bacterial ingestion by the simultaneous presence of liposomes in the extracellular medium, the failure to provide each phagosome with either sufticient amounts of myeloperoxidase or its substrate, H202 (16) , or the rapid disposal of hydrogen peroxide by the cytoplasmic enzyme, catalase. Thus, it has been possible to restore the oxidative metabolic capacities to CGD leukocytes by the introduction of G O containing liposomes to these cells and to attain moderate improvement in their bactericidal function in vitro. Further studies are required to design better methods to achieve complete restoration of bactericidal potency before in vivo studies with liposome therapy could be attempted.
CONCLUSION
Liposomes containing glucose oxidase and rendered phagocytic by coating with IgG were prepared. The enzyme within the liposome was demonstrated to be latent and could be activated upon treatment with detergent or after ingestion by PMN. The metabolic deficiency of CGD leukocytes could be markedly improved by the ingestion in vitro of these glucose oxidase containing liposomes. Glucose-1-"C oxidation activity and iodination were normalized, and the bactericidal activity was partially restored. These studies show that deficient oxidase activity can be restored into CGD leukocytes by selective ingestion of liposomes containing glucose oxidase.
